NKGen Biotech appoints Dr. Marco Gottardis to Board of Directors

NKGen Biotech, Inc.

Dr. Gottardis fills Class I director vacancy created by Alana McNulty's resignation, effective July 11, 2024.
Appointed to Audit, Compensation, and Nominating committees; annual retainer of $40,000 plus committee retainers.
Received sign-on option for 300,000 shares at $2.00 per share, vesting monthly over three years.
Background: former VP of Oncology Innovation at Janssen (JNJ) and Senior VP at Replay Bio Holdings.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Marco Gottardis

Director

NKGen Biotech, Inc.

Effective: 2024-07-11
Filed: July 12, 2024, 7:59 PM ET

On July 11, 2024, the Board, following a recommendation from the N&CG Committee, unanimously elected to have Dr. Marco Gottardis fill, effective immediately, the Class I director vacancy created by Ms. McNulty’s resignation and that Dr. Gottardis shall hold such position as a Class I director

Departed

Alana McNulty

Director

NKGen Biotech, Inc.

Effective: 2024-02-04
Successor: Dr. Marco Gottardis
Filed: July 12, 2024, 7:59 PM ET

Ms. Alana McNulty notified the Board of Directors of the Company (the “Board”) of her intention to resign as a director of the Company and as a member of our Audit Committee (the “Audit Committee”), Compensation Committee (the “Compensation Committee”) and Nomination and Corporate Governance Committee (the “N&CG Committee”), effective February 4, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Marco Gottardis was elected as Director at NKGen Biotech, Inc..

Action: elected
Role: Director

Exact text from the filing

On July 11, 2024, the Board, following a recommendation from the N&CG Committee, unanimously elected to have Dr. Marco Gottardis fill, effective immediately, the Class I director vacancy created by Ms. McNulty’s resignation and that Dr. Gottardis shall hold such position as a Class I director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alana McNulty resigned as Director at NKGen Biotech, Inc..

Action: resigned
Role: Director

Exact text from the filing

Ms. Alana McNulty notified the Board of Directors of the Company (the “Board”) of her intention to resign as a director of the Company and as a member of our Audit Committee (the “Audit Committee”), Compensation Committee (the “Compensation Committee”) and Nomination and Corporate Governance Committee (the “N&CG Committee”), effective February 4, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0001213900-24-060795

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.